One in 8 women is Diagnosed with breast cancer.
The PI3Kinase pathway plays a significant role in treatment resistant breast cancer.
Triple-negative breast cancer (TNBC) accounts for about 10-15% of all breast cancers. Triple-negative breast cancer cells do not express estrogen or progesterone receptors and also don’t make a protein called HER2.
Unique Treatment Challenges of TNBC
Hormone therapies and HER2 biologics
Chemotherapies or Radiation
immune molecules &
Overly active cell growth pathways including PI3K
Entering final preclinical studies in Glioblastoma with Medical College Of Wisonsin
Begin new study with Brown University on inhibiting Diffuse intrinsic pontine gliomas (DIPGS) brain tumors in children
Targeting for Phase 1
Clinical Trial in Glioblastoma
Targeting for Phase 2 Clinical Trial in Glioblastoma mid-
Targeting for Triple Negative Breast Cancer Phase 1 Clinical Trial with University of Colorado mid-year.
studies on the
inhibition of psoriasis.